Page Image

HR Breast Cancer

Back to Homepage
Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Advertisement

Expert Interviews

Advertisement
Advertisement
Latest Updates in Breast Cancer

April 15, 2025